PDCD1 and hereditary sensory and autonomic neuropathy: PD-1 inhibitors exhibit a higher incidence of CIP (3.6% vs. 1.3%) and a greater frequency of severe CIP (1.1% vs. 0.4%) compared to PD-L1 inhibitors [7].